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Introduction
In the present edition of Diabetologia, Nachnani and
colleagues report that rats treated with the glucagon-like-
peptide-1 (GLP-1) mimetic, exendin-4, for 75 days developed
low-grade pancreatitis [1]. The obvious question is whether
low-grade pancreatitis is also present in humans treated with
synthetic exendin-4 (exenatide) or other GLP-1-based
therapies? The paper by Nachnani et al. is a timely addition
to an area of growing interest and controversy in which, at
present, there are more questions than answers.
Pancreatitis induced by GLP-1 mimetic therapy:
the case against
The US Food and Drug Administration (FDA) raised
concerns over a possible association between treatment
with exenatide and subsequent onset of acute pancreatitis in
2008 [2]. The manufacturer of exenatide, the Amylin
Corporation, countered with two lines of argument [2].
First, they argued, there is no plausible biological
mechanism by which the GLP-1 mimetic, exenatide, would
induce pancreatitis. Given the paucity of experimental data
available on GLP-1 actions on the exocrine pancreas at that
time, the argument was a self-fulfilling prophecy. The paper
by Nachnani and colleagues [1] undermines that argument.
Second, Amylin argued that since pancreatitis is more
common in people with type 2 diabetes, the reported
pancreatitis following therapy with exenatide was ‘guilt by
association’ rather than a consequence of the therapy. This
argument has been bolstered by a report sponsored by Lilly
and the Amylin Corporation, which concludes that the
incidence of pancreatitis in type 2 diabetes patients is
comparable with the reported incidence of pancreatitis as an
adverse event in patients treated with exenatide [3]. In an
alternative approach, also sponsored by Amylin Pharma-
ceuticals, health insurance billing patterns in the USA
revealed no association between billing for diabetes
management with exenatide or with sitagliptin and subse-
quent billing for management of pancreatitis [4]. The
second argument cannot be fully supported by the studies
cited. First, adverse event reporting always greatly under-
estimates the frequency of events. Second, the insurance
claims approach is indirect and provides no guarantee that
patients who were prescribed and picked up a prescription
for a given medication actually took that medication. The
attrition rate for patients starting exenatide therapy is
relatively high.
A study in mice might offer some reassurance that GLP-
1-based therapy does not induce or exacerbate pancreatitis
[5]. Koehler and colleagues treated C57Bl/6 J mice with
exendin-4 (10 nmol/kg twice daily for 7 days) and then
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mice, the protocol was reversed, with caerulein preceding
exendin-4 treatment at the same dose for up to 6 days.
GLP-1 receptor activation increased exocrine pancreas
mass and induced genes associated with cellular prolifera-
tion, but had no effect on chemically induced pancreatitis.
In other studies in the same report, mRNA expression of a
variety of genes was quantified in pancreas of mice on a
high-fat diet followed by streptozotocin-induced diabetes
treated with exenatide (3 nmol/kg) or sitagliptin (370 mg/
kg/day). Transcription of genes considered important in the
induction of acute pancreatitis was not increased by either
of the GLP-1-based therapies. While the data of Koehler et
al. are a welcome addition to the sparse information on
potential actions of GLP-1 on the exocrine pancreas, the
study was limited in three ways: (1) a relatively small
number of animals was studied in each experiment (n∼5);
(2) GLP-1 mimetic therapy was of short duration; and (3)
pancreatic histology was not reported.
Pancreatitis induced by GLP-1 mimetic therapy:
the case for
The FDA has now also announced that more than 80 cases
of pancreatitis have been reported as adverse events in
relation to treatment with sitagliptin and have introduced a
label change to reflect this risk [6]. The number both of
published reports of pancreatitis following treatment with
exenatide and of cases reported to the FDA as adverse
events is increasing [7–9]. This could be a consequence of
increased awareness of the potential link. Prospective
randomised trials are a more appropriate way to establish
whether pancreatitis is indeed increased in connection with
GLP-1-based therapy. In one such study, the incidence of
pancreatitis was increased in patients with type 2 diabetes
treated with the GLP-1 analogue liraglutide [10]. However,
the incidence of symptomatic acute pancreatitis is relatively
low in patients treated with exenatide or liraglutide [10]. Is
this because the adverse effects (if any) of GLP-1 agonist
therapy on the exocrine pancreas are a rare idiosyncratic
event? Or, alternatively, is it because symptomatic pancre-
atitis in patients treated with GLP-1-based therapy is the
visible tip of an iceberg, with varying degrees of more
subtle asymptomatic changes in the exocrine pancreas
being more commonly present (Fig. 1)?
The report in the current issue of Diabetologia provides
some insight in that regard [1]. Ten non-diabetic Sprague–
Dawley male rats were treated from 8 weeks of age with
daily injections of exendin-4 (10 μg/kg) for 75 days. The
dose used exceeded that used in humans (10–20 μg per
day). As expected, treated rats had lower circulating insulin
Fig. 1 The occasional acute episode of pancreatitis in some individuals treated with GLP-1-based therapy along with the suggestion from animal
studies [1, 11] suggest that asymptomatic chronic pancreatitis may not be an uncommon consequence of GLP-1 based therapy. Rx, treatment
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weight, presumably due to less fat (leptin was lower).
Evidence of chronic pancreatitis is presented histologically
(loss of usual acinar structure, irregularly shaped and sized
acinar cells, inflammation and fibrosis) and by increased
circulating lipase (but not amylase) levels.
Given that numerous animal toxicology studies were
presumably undertaken for exenatide to obtain approval
from the FDA, why was pancreatitis not picked up in those
studies? One possibility is that the low-grade pancreatitis
detected and characterised in the present studies may have
been insufficient to be noted in animal toxicology studies.
The animals were apparently healthy despite the low-grade
pancreatitis and macroscopic abnormalities of the pancreas
may not have been visible at necropsy.
We also observed unexpected changes in the exocrine
pancreas of 8-week-old Sprague–Dawley rats transgenic for
human islet amyloid polypeptide (HIP rats) when on a
high-fat diet and treated for 12 weeks with the dipeptidyl
peptidase-4 inhibitor sitagliptin, 200 mg kg
−1 day
−1 [11].
One sitagliptin-treated rat had regional haemorrhagic
pancreatitis. Others had acinar to ductal metaplasia; and
all had increased ductal replication, both characteristics of
chronic pancreatitis. As in the study presented in the current
edition of Diabetologia [1], we did not observe behavioural
changes suggestive of symptomatic pain in the treated rats.
Food intake and growth were also normal. Again, it is
unlikely that those changes would have been detected by
routine toxicology screening, which does not include
measures of cell turnover or screen for subtle changes such
as ductal metaplasia.
These studies [1, 11] raise the possibility that GLP-1-
based therapy by injection of GLP-1 agonist or use of a
dipeptidyl peptidase-4 inhibitor to enhance endogenous
GLP-1 levels could induce undetected low-grade asymptom-
atic chronic pancreatitis more commonly than the rare events
of symptomatic pancreatitis. To further consider how GLP-1-
based therapy might induce chronic pancreatitis, we first
briefly consider the pathophysiology of chronic pancreatitis.
Pathophysiology of chronic pancreatitis?
Pancreas originates as ventral and dorsal buds of the
primitive gut endoderm, which fuse to form the pancreas.
Subsequently, through the actions of sequential programmes
of development, definitive cell types arise. The pancreatic
epithelium is marked by production of transcription factor
pancreatic and duodenal homeobox 1 (PDX1; also referred
to as insulin upstream factor 1 [IPF1]) and lineage tracing
shows that all mature cell types in the pancreas originate
from these PDX1-producing epithelial cells [12]. The
branching tips of the growing pancreatic epithelium form
domains of multipotent progenitor cells that give rise to
differentiated cells. At mid-gestation, these branching tips
undergo a developmental switch that converts them into
exocrine cells. Endocrine cells emerge from duct-like
structures that are centrally located within the trunk of the
pancreatic epithelium and migrate to form islets. The
regulation of cell proliferation of progenitor cells and
differentiation of cell fates is coordinated by Notch
homologue (NOTCH) signalling through activation of hairy
and enhancer of split 1 [13]. The canonical wingless-type
MMTV integration site family (WNT) pathway is essential
for proliferation of pancreatic epithelium [14] and condi-
tional disruption of pancreatic beta-catenin production, a
downstream target of WNT signalling, resulted in pancre-
atic hypoplasia [15]. Gain of function experiments in
pancreatic islets have shown that WNT signalling can
promote islet proliferation [16]. Stabilisation of beta-catenin
results in the formation of large pancreatic tumours [17].
The adult exocrine pancreas consists of pyramid-shaped
acinar cells surrounding an acinus, into which the exocrine
secretions are discharged. These secretions are then con-
veyed by small pancreatic ducts through the pancreatic
ductal tree, eventually reaching the duodenum. Given the
potent capacity for misdirected pancreatic enzymes to
autodigest adjacent tissue, the integrity of the relationship
between the acini and their attendant ducts is important [18].
Factors known to increase the risk of pancreatitis include
excessive alcohol consumption, viral infection, obesity and
diabetes [3, 19–21]. An important genetic component that
enhances predisposition for the development of pancreatitis
is emerging. Known predisposing genetic factors for
pancreatitis can be broadly divided into those that enhance
or prolong the activity of trypsin [22, 23], or those that
increasethe viscosityandimpedethe flowofductalsecretions
[24]. Thus primacy to initiate pancreatitis can be attributed to
either duct or acinar cells. If the microanatomy of the acinar–
ductal relationship is disturbed, the basis for longer standing
chronic pancreatitis is established.
In chronic pancreatitis increased ductal replication is a
consistent feature [19–21]. It has been suggested that this
represents attempted pancreas regeneration by recapitulat-
ing the original formation of pancreatic acini in relation to
branching pancreatic ducts [25]. The concept that local
damage and inflammation induces recruitment of somatic
stem cells to permit repair was established in the transected
flatworm [26] and is likely to be a general phenomenon.
Increased ductal replication has also been proposed as
contributing to chronic pancreatitis by helping distort and
obstruct small pancreatic ducts [19–21].
In conclusion, pancreatitis may be initiated at the level of
acinar cells or duct cells. Once the microanatomy of the
acinar–ductal system has been disturbed, aberrant delivery
of pancreatic enzymes leads to local inflammation and
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latter are likely to be the signals that induce chronic
increased ductal proliferation, which in turn leads to
distorted ducts, obstructed flow and sustained chronic
pancreatitis. How does the increased risk of chronic
pancreatitis in patients with obesity and/or type 2 diabetes,
and perhaps in those on GLP-1 therapy fit into this model?
Chronic pancreatitis in patients with diabetes
and on GLP-1 therapy: ductal hyperplasia
as a common precursor?
Pancreatic ductal replication is increased in humans with
obesity and/or type 2 diabetes [27], providing a possible
link between the increased risk of pancreatitis in individuals
with obesity and/or type 2 diabetes.
The mechanisms that induce increased pancreatic ductal
replication in individuals with obesity and/or type 2
diabetes are unknown. Excessive fat accumulation in
pancreas could induce local inflammation [27]. Increased
beta cell apoptosis in type 2 diabetes is also associated with
inflammation [28] and may, through local cytokines, foster
attempted islet regeneration via duct-related progenitors,
comparable to the process proposed for acinar tissue in
chronic pancreatitis. GLP-1 therapy has also been proposed
to activate regenerative efforts in relation to pancreatic
ducts, with increased duct cells positive for PDX-1 [29].
In common with humans with obesity and type 2
diabetes, pancreatic ductal replication was increased in the
HIP rat model of type 2 diabetes (Fig. 2)[ 11]. Moreover,
the increase in ductal replication in this model is amplified
with sitagliptin therapy [11]. It is unknown if GLP-1
therapy also amplifies the increased ductal replication rates
present in humans with obesity and type 2 diabetes. If so,
this would be a potential mechanism to increase the risk of
chronic pancreatitis by distortion of small pancreatic ducts.
GLP-1-based therapy may also induce pancreatitis by its
known actions of altering enzyme secretion [30] and/or of
promoting replication of acinar cells, thereby disturbing the
acinar architecture. Interestingly, Nachnani and colleagues
in the present edition of Diabetologia noted that acinar cells
were abnormal in appearance and had a greater frequency
of cell death [1]. In the shorter term studies of Koehler and
colleagues, GLP-1 mimetic therapy led to an increase in
pancreas size, implying increased cell formation [5].
Thus, while it remains unknown exactly how GLP-1
mimetic therapy might induce pancreatitis, plausible hy-
potheses as to how it might be mediated already exist and
are worthy of further investigation.
Does low-grade pancreatitis matter?
There would indeed be grounds for concern if GLP-1
mimetic therapy were found to lead to chronic asymptom-
atic low-grade pancreatitis. Low-grade chronic pancreatitis
is a well established risk factor for pancreatic adenocarci-
noma [31, 32], a disease that is invariably diagnosed late
with a 5 year life expectancy of less than 10%. Increased
ductal replication, most frequently due to chronic pancre-
atitis, is considered to be the first stage in a progression of
morphological stages that may lead to pancreatic adeno-
carcinoma [32]. The next stage is acinar to ductal
metaplasia, observed in HIP rats treated for 12 weeks with
sitagliptin [11]. With time, the increased ductal replication
may lead to intraductal neoplasia, with progression there-
after to pancreatic cancer (the progression being classified
by the advancing morphological stages known as pancreatic
intra-epithelial neoplasias [PanIns]) [31].
Fortunately, the majority of individuals with chronic
pancreatitis and increased ductal replication do not progress
to pancreatic cancer. Both germ line and somatic mutations
have been identified that predispose to pancreatic cancer
[32]. However, these mutations do not seem to be required
for the increased risk of pancreatic cancer seen in
individuals with type 2 diabetes [33, 34]. The risk of
chronic pancreatitis progressing to pancreatic adenocarci-
noma increases with duration of pancreatitis. The cumula-
tive risk for patients with hereditary pancreatitis of
developing pancreatic cancer was reported as 10% at age
50 years, 19% at age 60 years and 54% at 75 years [35].
In conclusion, if GLP-1 mimetic therapy does induce
low-grade pancreatitis superimposed on that present as a
result of obesity and/or type 2 diabetes, then there would be
Fig. 2 Quantification of ductal cell replication in wild-type (WT) and
HIP (H) rats, and in HIP rats treated with sitagliptin (HS), metformin
(HM) or a combination of both (HSM) for 12 weeks. *p<0.05 for H vs
WT; ***p<0.001 for HS vs all groups; †p<0.05 for HM vs H and HS;
‡p<0.001 for HSM vs HS. (Reprinted with permission of the American
Diabetes Association, Inc., © 2009 from Matveyenko et al. [11])
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drugs may lead to increased risk of pancreatic adenocarci-
noma. While GLP-1-based drugs offer some advantages as
therapies, no advantages could outweigh even a modestly
increased risk of developing pancreatic adenocarcinoma.
Moreover, metformin therapy decreases the risk of pancre-
atic cancer [36]. Indeed, several mechanisms have been
proposed by which metformin may decrease the incidence
of several cancers [37]. Intriguingly, metformin counters
the actions by which sitagliptin amplifies pancreatic ductal
replication in HIP rats (Fig. 2)[ 11]. On that basis, until
more information is available on the effects of GLP-1-based
therapy on the exocrine pancreas in humans, it would be
prudent to use GLP-1 mimetic therapy only in addition to
metformin.
Where to go from here?
The limitations of post-marketing adverse event reporting
are well known. They have recently been highlighted by the
debate on the risks of cancer in connection with use of
insulin glargine (A21Gly,B31Arg,B32Arg human insulin)
[34]. To make matters worse, the submerged part of the
iceberg, asymptomatic pancreatitis (Fig. 1), is undetectable
in clinical studies. One strategy is to wait until there is a
clear sign of increased pancreatic adenocarcinoma in
connection with GLP-1-based treatment, the usual approach
of regulatory authorities.
Is that a wise strategy? How, for example, would we
detect that signal with current post-marketing surveil-
lance? Pancreatic cancer is already increased in type 2
diabetes and would predictably be underreported. Post-
marketing databases maintained by pharmaceutical com-
panies report rates of cancers far below those of the
general population, so are of little value in tracking such
an association. We agree with the recent proposal that new
mechanisms are needed to track outcomes, expected and
unexpected, in patients with diabetes on new and older
therapies [34]. To avoid conflict, these data bases should be
managed independently of the companies marketing the
treatments.
Clearly we also need more information on the actions of
GLP-1-based treatment on the exocrine pancreas and
possibly on other cell types such as the C-cells of the
thyroid gland, which also appeared to show increased
tumour formation in animal testing of liraglutide [38]. The
paper by Nachnani in the current edition of Diabetologia
[1] is a welcome addition to these as yet limited data [31].
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